abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
93093: Pain Management, Buprenorphine with Confirmation including Naloxone Print View
Buprenorphine IA  < 5  ng/mL 
Buprenorphine MASS SPEC  < 2  ng/mL 
Norbuprenorphine MASS SPEC  < 2  ng/mL 
Naloxone MASS SPEC  < 2  ng/mL 

PRIMARY
1 Urine 20 (7) mL   Room Temperature - 7 Day(s)/Refrigerated - 14 Day(s)/Frozen - 30 Day(s)  
ALTERNATE

Patients treated with buprenorphine-naloxone co-formulation will demonstrate both naloxone and buprenorphine/norbuprenorphine drug analysis. Naloxone is not detected with buprenorphine-only use.

20 mL (7 mL minimum) urine collected in a clinical drug test
transport vial
Setup Schedule
Monday-Saturday

Reported (Analytical Time)
3 days

CPT Codes
80307,80348,80362

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Reject Criteria: Preserved samples






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database